10
May

08:00 AM PDT

Oncology

Name: Oncology Conferences 2023
Start: 2023-05-10T08:00
End: 2023-05-10T16:50
Location: Hard Rock Hotel San Diego

Strategy Meeting West Coast USA 2023

Exploring Promising Areas in Oncology Research Aimed to Expand Our Knowledge Base, Address Unmet Medical Needs and Improve Overall Clinical Success

Hard Rock Hotel San Diego

Strategy Meetings

Transforming the way we network

Often at conferences, seminars and summits you are placed amongst a large pool of industry professionals, however the opportunity to share personal insights and knowledge is limited. With Proventa International?s unique format of executive roundtables, you are placed side by side with those same industry leaders, in private, facilitated discussions on pre-selected topics.rn

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the West Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Meet Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at Oncology Strategy Meeting.

Ana Krtolica

Senior Vice President, Preclinical Development Oryn Therapeutics

Anna Vardanyan

Vice President, Business Development Inmagene Biopharma

Oscar Segurado

Chief Medical Officer ASC Therapeutics

Oscar Segurado is an executive veteran of the biopharmaceutical industry with extensive global leadership experience in translational science, clinical development and global medical affairs. C-suite executive and industry leader providing in-depth expertise for pre-clinical and clinical study strategy, planning, execution and monitoring, regulatory interactions, investor relations, fundraising, M&A and IPO process and deliverables. Chief Medical Officer for ASC Therapeutics, former CMO for Symvivo, Myriad Genetics and CellMax Life, Vice President for Becton Dickinson and Global Medical Head for Abbott/AbbVie (Humira). Author and co-author of over 100 peer-reviewed publications, including Nature, Lancet and Journal of Experimental Medicine, books and medical articles and member of several scientific and medical societies. Holding a tenured Professorship of Immunology at the University of Leon, Spain. Received PhD from the University of Wuerzburg, Germany and MD from the University of Salamanca, Spain.

Boris Minev

President, Medical & Scientific Affairs Calidi Biotherapeutics

Charles Theuer

President & CEO TRACON Pharmaceuticals

Dr. Theuer has served as President, Chief Executive Officer and a member of the board of directors of TRACON Pharmaceuticals since July 2006. From 2004 to 2006, Dr. Theuer was the Chief Medical Officer and Vice President of Clinical Development at TargeGen, Inc., a biotechnology company, where he led the development of small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease. Prior to joining TargeGen, Inc., Dr. Theuer was Director of Clinical Oncology at Pfizer, Inc., a pharmaceutical corporation, from 2003 to 2004. At Pfizer, Dr. Theuer led the clinical development of Sutent® in kidney cancer; Sutent® was approved by the U.S. Food and Drug Administration in 2006 for the treatment of advanced kidney cancer. Dr. Theuer has also held senior positions at IDEC Pharmaceuticals Corp. from 2002 to 2003 and at the National Cancer Institute from 1991 to 1993. In addition, he has held academic positions at the University of California, Irvine, where he was Assistant Professor in the Division of Surgical Oncology and Department of Medicine. Dr. Theuer received a B.S. from the Massachusetts Institute of Technology, an M.D. from the University of California, San Francisco, and a Ph.D. from the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997.  Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology.

Gajanan Bhat

Vice President Clinical Sciences Spectrum Pharmaceuticals

Gregory Opiteck

Vice President Head of Translational Sciences Allogene Therapeutics

Jack Florio

Managing Director Weild & Co

Jason B. Litten

Chief Medical Offficer Chimeric Therapeutics

Joanne Sloan Lancaster

Vice President, Program Team Leadership NGM Bio

Joe Stalder

Executive Director Project Management Mirati Therapeutics

Karin Zeh

Vice President, Program and Alliance Management Genesis Therapeutics

Majid Ghoddusi

Executive Director, Clinical Biomarker Poseida Therapeutics

Matthew Spear

Chief Development Officer / Chief Medical Officer Denovo Biopharma

Dr. Spear has been working in oncology and gene therapy research and development for over 30 years. He received a B.A. degree from Johns Hopkins University and an M.D. degree from Stanford University. Post-graduate training was in the Massachusetts General Hospital / Harvard University program. He has served as an Associate Professor on the faculty of the USC Keck School of Medicine, and the UCSD Medical School / UCSD Cancer Center where he managed a clinical practice, drug discovery/gene therapy research, and clinical trial programs for cancer. Dr. Spear led multiple oncology clinical development programs at Pfizer. He subsequently served as Chief Medical Officer and Senior Vice-President at Nereus Pharmaceuticals, followed by Head of Oncology and Head of Biotherapeutics at Sunovion Pharmaceuticals, then as a Vice-President at Incyte and Sangamo Therapeutics, and Chief Medical Officer at Poseida Therapeutics developing multiple CAR-T cell and gene therapy products. He is currently Chief Development Officer / Chief Medical Officer at Denovo Biopharma. He has also served as a CIRM CAR-T cell principal investigator, NIH / NCI study section, CPRIT grant review panel, biotechnology and pharmaceutical advisory boards, IRB/SRC, and scientific journal editorial review committees related to cancer and gene therapy, as well as authoring numerous scientific papers and patent applications.
CAR-T cell, RMAT, Gene Therapy, Gene Editing, AAV, HSV, transposon, hemophilia, Oncology, Hematology, NHL, myeloma, AML, MDS, prostate cancer, lung cancer, breast cancer, pancreatic cancer, GBM, H&N cancer, sarcoma, ovarian cancer, Oncolytic, Epigenetic, Biomarkers, Companion Diagnostics. Small Molecules, California Institute for Regenerative Medicine (CIRM), Immunotherapy, Vaccine, Antibody, Phage Display, sickle-cell, thalassemia, MPS I&II, MEK, PARP, CDK, VEGFR, Angiogenesis, VDA, HDAC, Proteosome, PI3K, BRD, JAK, PIM, FGFR, WT1, lysine-specific demethylase, OTC

Hui Zou

Chief Scientific Officer (CSO) Phanes Therapeutics

Nathaniel Wang

Chief Executive Officer and Co-Founder Replicate Biosciences

Ron Shazer

Vice President of Cllnical Development Mirati Therapeutics

Stan Jin

Co-founder and Chief Executive Officer Molecular Axiom

Will Robberts

President LIPAC Oncology

See the agenda and facilitator line-up. Download the strategy meeting brochure for full details.

DOWNLOAD THE BROCHURE

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

There’s only so much you can learn from presentations and lectures. Instead our interactive Roundtable Discussions let you debate the topics that really matter

Senior Decision Makers

All our Strategy Meetings are aimed at director level and above. Discover how your peers are tackling the industries biggest challenges and have your thoughts heard

Personalised Agendas

Pick the roundtable discussions that you want to be part of. Simply choose your sessions and we’ll create a personalised agenda just for you

Private and Intimate Networking

Small group discussions, private meetings, networking drinks – however you choose to make those important connections our Strategy Meetings have the solution

Agenda

See Which Topics Are Up For Discussion

09:00

Roundtable Tracks

Immuno-Oncology Reprogramming The Tumor Microenvironment(TME) To Improve Immunotherapy Outcomes -Boris Minev President, Medical & Scientific Affairs, Calidi Biotherapeutics Targeted Therapy Improving Cancer Combination Therapy By Timing Drug Administration -Oscar Segurado Chief Medical Officer, ASC Therapeutics Precision Medicine/ Companion Diagnostics Beyond Genomics What Is The Potential And What Are Barriers To Multi Omics Profiling -Ana Krtolica Senior Vice President, Preclinical Development, Oryn Therapeutics Biomarker Discovery Employing the circulations of tumor DNA (ctDNA) as a biomarker or an early endpoint in early-stage solid tumor clinical trials -Majid Ghoddusi Executive Director, Clinical Biomarkers, Janux Therapeutics Clinical Research & Development Incorporating real-world-evidence in the clinical development process for faster submissions and accelerated approvals -Gajanan Bhat Senior Vice President, Clinical Sciences, Spectrum Pharmaceuticals (New) Investment, Private Equity & Venture Capital Partnerships Creative Solutions For Funding Early Stage Oncology Innovation -Will Robberts President, LIPAC Oncology

11:10

Roundtable Tracks

Immuno-Oncology Latest Innovations In Immunooncology To Unleash Better And More Effective Immunotherapy Options -Nathaniel Wang Chief Executive Officer and Co-Founder, Replicate Biosciences Targeted Therapy Addressing Operational Challenges Of Developing Targeted Therapies To Treat Increasingly Precise Oncologic Mutations -Joe Stalder Executive Director Project Management, Mirati Therapeutics -Ron Shazer Vice President of Cllnical Development, Mirati Therapeutics Precision Medicine/ Companion Diagnostics Biomarker Discovery Examining How Integrated Approaches To Cancer Biomarker Discovery May Reveal How Predictive Gene Signatures Are Of Cancer Progression Clinical Research & Development Evaluating The Benefits Of In House Clinical Development And Operations -Charles Theuer Chief Executive Officer, TRACON Pharmaceuticals Investment, Private Equity & Venture Capital Partnerships Best Practices And Success Factors To Raising Funds And Building An Innovative Biotech Company Which Assets And Technologies Investors Will Be Looking For In Your Intellectual Property Portfolio -Anna Vardanyan Vice President, Business Development, Inmagene Biopharma

13:40

Roundtable Tracks

Immuno-Oncology Advancing Cell Therapies For Solid Tumor Patients -Jason B. Litten Chief Medical Offficer, Chimeric Therapeutics Targeted Therapy Gene Therapy Targeting With Replicating Vector -Matthew Spear Chief Development Officer / Chief Medical Officer, Denovo Biopharma Precision Medicine/ Companion Diagnostics Trends Challenges Controversies And Cost Considerations Of Precision Oncology Approaches And Targeted Therapies -Karin Zeh Vice President, Program and Portfolio Management, Bristol Myers Squibb Biomarker Discovery Applications Of Biomarkers To Enhance Response To Immuno-oncology Therapeutics -Hui Zhou Chief Scientific Officer, Phanes Therapeutics, Inc. Clinical Research & Development Challenges And Opportunities In Oncology Clinical Development -Joanne Sloan Lancaster Vice President, Program Team Leadership, NGM Bio Investment, Private Equity & Venture Capital Partnerships An Insight Into The Investor Mindset How To Identify Analyse And Mitigate Risk In A Competitive Market -Stan Jin Co-founder and Chief Executive Officer, Molecular Axiom –(Co-facilitating) Jack Florio Managing Director, Weild & Co

Become an official strategy meeting partner. Whatever your business needs, we can help. Get in touch for partnering opportunities.

I’D LIKE TO PARTNER

Press play to hear what your colleagues had to say…

Quick Links

Want to find out more?

Find out more details about our Strategy Meetings and other news and events.

Here To Help

Need help registering your team? Just get in touch and a member of the team will be happy to help.

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D San Diego

Drug Discovery Biology & Bioinformatics Strategy Meeting West Coast USA 2024

Oncology

Strategy Meeting West Coast USA 2023

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Hard Rock Hotel San Diego

Transforming the way we network

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Meet Our Facilitators

Ana Krtolica

Anna Vardanyan

Oscar Segurado

Boris Minev

Charles Theuer

Gajanan Bhat

Gregory Opiteck

Jack Florio

Jason B. Litten

Joanne Sloan Lancaster

Joe Stalder

Karin Zeh

Majid Ghoddusi

Matthew Spear

Hui Zou

Nathaniel Wang

Ron Shazer

Stan Jin

Will Robberts

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

See Which Topics Are Up For Discussion

Opening Keynote

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

Roundtable

Roundtable Tracks

Networking Lunch

Roundtable

Roundtable Tracks

Networking/1-1 Meetings

PANEL DISCUSSION

Drinks Reception

Co-Host Sponsors

Key Opinion Leader

Press play to hear what your colleagues had to say…

Want to find out more?

Here To Help

Select days you wish to attend You can add multiple days

Daily Delegate Rate includes:

VAT Excluded

Select days you wish to attend You can add multiple days

Pass includes:

VAT Excluded

About You

Your Address

About Your Company

This is required field*

Bone/Osteoporosis

Immunology

Orthopaedics

Cardiovascular

Infectious diseases

Pulmonology

CNS

Inflammation

Hard Rock Hotel San Diego